← Back to Analyst Consensus 
TVRD Buy
Tvardi Therapeutics, Inc.
Current Price —
Implied Upside —
Analysts 15
30-Day Momentum
▲ 1 upgrades / ▼ 0 downgrades / 0 reiterations from 1 firms
Next Earnings
Nov 12, 2026 (16 days)
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Oct 20, 2026 | Chardan Capital | initiate | — → Buy | — | 46% |
| Jul 30, 2026 | BTIG | maintain | Buy → Buy | — | 52% |
| Jul 8, 2026 | Raymond James | upgrade | Market Perform → Outperform | — | 53% |
| Jul 7, 2026 | BTIG | reiterate | Buy → Buy | — | 52% |
| Jun 8, 2026 | HC Wainwright & Co. | initiate | — → Buy | — | 44% |
| Apr 20, 2026 | Barclays | downgrade | Equal-Weight → Underweight | — | 53% |
| Apr 1, 2026 | Barclays | maintain | Equal-Weight → Equal-Weight | — | 53% |
| Apr 1, 2026 | Piper Sandler | maintain | Neutral → Neutral | — | 54% |
| Apr 1, 2026 | BTIG | reiterate | Buy → Buy | — | 52% |
| Oct 14, 2025 | Raymond James | downgrade | Outperform → Market Perform | $0 | 53% |
| Oct 13, 2025 | BTIG | maintain | Buy → Buy | $15 | 52% |
| Oct 13, 2025 | Barclays | initiate | — → Overweight | $61 | 53% |
| Jul 14, 2025 | Raymond James | initiate | — → Outperform | $62 | 53% |
| Jul 11, 2025 | Cantor Fitzgerald | initiate | — → Overweight | $52 | 50% |
| Jun 12, 2025 | Piper Sandler | initiate | — → Overweight | $78 | 54% |
| May 21, 2025 | Oppenheimer | initiate | — → Outperform | $65 | 52% |
| Apr 28, 2025 | Jones Trading | initiate | — → Buy | $39 | 50% |
Price Target Trend
Apr 1, 2026 Oct 27, 2026
EPS Estimates
+1q —
0q —
0y —
+1y —
Cross-Platform Signals
No cross-platform signals in the last 90 days